Jiangsu Genscend Biopharmaceutical

Genscript ProBio, formerly known as Jiangsu Genscend Biopharmaceutical, is a leading global contract development and manufacturing organization (CDMO) specializing in biologics and advanced therapies. As a subsidiary of GenScript Biotech Corporation, the company provides end-to-end solutions ranging from drug discovery and process development to clinical and commercial manufacturing. Their expertise spans various modalities, including monoclonal antibodies, bispecifics, cell therapies, and gene therapies (GCT). With state-of-the-art facilities in China and a growing global presence, Genscript ProBio supports biopharmaceutical innovators in accelerating the development of life-saving medicines through integrated technology platforms and rigorous quality standards.